Newron, Zambon sign collaboration and licence agreement for Safinamide
As per the agreement, Zambon will initially invest €20m into Newron, covering the completion of safinamide’s clinical development and the preparation of the application for marketing approval in
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.